Related Experiment Video
Updated: May 31, 2026
Strategies for Study of Neuroprotection from Cold-preconditioning
Published on: September 2, 2010
Ceftriaxone preconditioning confers neuroprotection in neonatal rats through glutamate transporter 1 upregulation
Kazuya Mimura1, Takuji Tomimatsu, Kenji Minato
1Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Insights
Ceftriaxone preconditioning boosts glutamate transporter 1 (GLT-1) in neonatal brains, reducing brain damage after hypoxic-ischemic injury. This suggests ceftriaxone as a potential prophylactic strategy for neonatal encephalopathy.
Area of Science:
- Neuroscience
- Neonatal Medicine
- Pharmacology
Background:
- Neonatal encephalopathy poses a significant threat to infant brain development.
- Glutamate excitotoxicity, mediated by impaired glutamate transport, is a key factor in neonatal brain injury.
- Glutamate transporter 1 (GLT-1) plays a crucial role in regulating extracellular glutamate levels.
Purpose of the Study:
- To investigate if ceftriaxone preconditioning can protect against neonatal brain damage.
- To determine if ceftriaxone upregulates glutamate transporter 1 (GLT-1) expression in the neonatal brain.
- To assess the impact of ceftriaxone on neuronal damage and survival following hypoxic-ischemic (H-I) injury.
Main Methods:
- Neonatal rats were pretreated with ceftriaxone or other agents.
- GLT-1 and GLAST mRNA and protein levels were measured in P7 brains.
- Rats underwent a hypoxic-ischemic (H-I) procedure or sham operation.
- Neuronal damage (H&E, MAP-2) and cell death (TUNEL) were assessed at P14.
Main Results:
- Ceftriaxone treatment significantly increased GLT-1 mRNA and protein levels, but not GLAST.
- Following H-I injury, ceftriaxone preconditioning resulted in a larger MAP-2 positive area, indicating preserved neurons.
- Ceftriaxone preconditioning led to a decrease in TUNEL-positive cells, signifying reduced apoptosis.
Conclusions:
- Ceftriaxone preconditioning demonstrates neuroprotective effects in the immature brain.
- Upregulation of GLT-1 appears to be a key mechanism underlying ceftriaxone's neuroprotection.
- Antenatal ceftriaxone may serve as a novel prophylactic strategy against neonatal encephalopathy.
Objective:
This study investigated the hypothesis that ceftriaxone preconditioning ameliorates brain damage in neonatal animals through glutamate transporter 1 (GLT-1) upregulation.
Study Design:
Sprague Dawley rats were pretreated with ceftriaxone, erythromycin, minocycline, or saline for 5 consecutive days starting from postnatal day 2 (P2), and GLT-1/glutamate-aspartate transporter (GLAST) messenger RNA (mRNA) and protein levels were examined in the P7 brains. After ceftriaxone or saline preconditioning, the P7 rats underwent hypoxic-ischemic (H-I) procedure or sham operation. One week after the procedure (P14), hematoxylin-eosin staining, microtubule-associated protein 2 (MAP-2) immunostaining, and transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) assay were used to examine neuronal damage and possible neurotoxicity.
Results:
Repeated ceftriaxone injections significantly increased GLT-1 mRNA and protein levels but not GLAST. Following such treatment and H-I procedure, the MAP-2-positive area increased and TUNEL-positive cells decreased.
Conclusion:
Antenatal ceftriaxone may help to provide neuroprotection in the immature brain and become a new prophylactic strategy to reduce neonatal encephalopathy in clinical perinatal medicine.
